Inhibition of RET and KIT supports its therapeutic role in thyroid cancers and gastrointestinal stromal tumors (GIST), particularly in the context of resistance to earlier-generation TKIs [109]. The gene discussed is RET; the disease is gastrointestinal stromal tumor.